Phio Pharmaceuticals Corp. 10-Q

ITEM 5. OTHER INFORMATION None. ITEM 6. EXHIBITS EXHIBIT INDEX Incorporated by Reference Herein Exhibit Number Description Form Date 31.1 Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer and Principal Financial Officer. * 32.1 Sarbanes-Oxley Act Section 906 Certification of Principal Executive Officer and Principal Financial Officer . * 101 The following financial information from the Quarterly Report on Form 10-Q of Phio Pharmaceuticals Corp. for the quarter ended March 31, 2021, formatted in XBRL (eXtensible Business Reporting Language): (1) Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020; (2) Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2021 and 2020; (3) Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2021 and 2020; (4) Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020; and (5) Notes to Condensed Consolidated Financial Statements (Unaudited).* * Filed herewith. 24 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Phio Pharmaceuticals Corp. By: /s/ Gerrit Dispersyn Gerrit Dispersyn, Dr. Med. Sc. President and Chief Executive Officer Date: May 13, 2021 25